ArticlePloS one2017
Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: A Korean nationwide prospective cohort study.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Proton pump inhibitors and colorectal cancer: A systematic review.World journal of gastroenterology · 2021Pooled it
- Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies.International journal of colorectal disease · 2020Pooled it
- The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis.European journal of clinical pharmacology · 2020Pooled it
- Proton pump inhibitors and all-cause mortality in colorectal cancer.Scientific reports · 2025Article
- Proton Pump Inhibitors and Oral-Gut Microbiota: From Mechanism to Clinical Significance.Biomedicines · 2024Review
- Maintenance proton pump inhibitor use and risk of colorectal cancer: a Swedish retrospective cohort study.BMJ open · 2024Article
- Proton pump inhibitors and risk of gastrointestinal cancer: A meta‑analysis of cohort studies.Oncology letters · 2024Article
- Article
- Operational Definitions of Colorectal Cancer in the Korean National Health Insurance Database.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2023Review
- Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women's Health Initiative.Nutrition and cancer · 2023Article
- Re-thinking the possible interaction between proton pump inhibitors and capecitabine.Cancer chemotherapy and pharmacology · 2022Review
- Association between Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma: A Korean Nationally Representative Cohort Study.Journal of clinical medicine · 2022Article
- Anticoagulant drugs with or without proton pump inhibitor and colorectal cancer risk: a population-based, case-control study.BMC gastroenterology · 2022Article
- Proton Pump Inhibitors and Cancer: Current State of Play.Frontiers in pharmacology · 2022Review
- Association between the chronic use of gastric acid suppressants and high-risk colorectal polyps.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study.Prostate cancer and prostatic diseases · 2020Article
- Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.Journal of gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDespite plausible mechanisms, the clinical significance of long-term proton pump inhibitor (PPI) use to colorectal cancer (CRC) remains unknown. The purpose of this study was to investigate the association between PPI use and CRC development.
methodsWe conducted a population-based prospective cohort study using the Korean nationwide claims database merged with national health examination data. The study cohort included a total of 451,284 participants who were tracked to identify cases of CRC since 2007. We assessed and standardized PPI use before the index date using the Defined Daily Dose system. We calculated the hazard ratios and their 95% confidence intervals to assess the association between PPI use and CRC occurrence using Cox proportional hazard regression models with adjustment for potential confounders. We performed subgroup analyses of the effect of PPI exposure on CRC development stratified by the CRC risk.
resultsThere were 5,304 cases of CRC during the study period of 2,908,152 person-years. PPI use was not associated with CRC risk overall. The incidence of CRC was higher among individuals who were elderly, male, more obese, and drank alcohol more frequently and among those who had more comorbidities. Further subgroup analyses revealed that the hazard effect of PPI use increased linearly in a dose-dependent manner with the number of CRC risk factors for which the risk level was considered low.
conclusionWithin the low-risk population, PPI use was associated with an increased risk of CRC, although the association did not weigh the effects of conventional risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.